Lostad T50

Composition: Losartan

Indications:
Treatment of hypertension: Particularly in patients who develop a cough when using angiotensin-converting enzyme inhibitors and to reduce the risk of stroke in patients with left ventricular hypertrophy.
Treatment of kidney disease in diabetic patients: Serum creatinine levels between 1.3 - 3.0 mg/dL in patients < 60 kg and 1.5 - 3.0 mg/dL in males > 60 kg with proteinuria.
Treatment of heart failure and myocardial infarction.

Population: Lostad T50 is administered orally.

Dosage:
Adults: The usual dose is 50 mg once daily. If necessary, the dose can be increased to 100 mg once daily or divided into two doses per day. The maximum antihypertensive effect is achieved approximately 3 - 6 weeks after starting treatment.
Initial dose: 25 mg once daily for patients with intravascular volume depletion. This dose is also suitable for patients with hepatic or renal impairment.
Children: For children aged 6 years and older with hypertension, the initial dose is 0.7 mg/kg once daily, up to a maximum of 50 mg, with dose adjustments based on response; doses higher than 1.4 mg/kg or 100 mg/day have not been studied.
Kidney disease in type 2 diabetic patients: The initial dose is 50 mg once daily, which can be increased to 100 mg once daily depending on blood pressure response.

Contraindications: Lostad T50 is contraindicated in patients with hypersensitivity to the active ingredient or any excipients of the medication.

Cautions: The above dosage is for reference only. Specific dosage depends on the patient’s condition and disease progression. For appropriate dosage, consult your doctor or healthcare professional.

Storage: Store in a tightly closed container, in a dry place, protected from light, at temperature below 30°C."


Buy now

Film coated tablets

UPDATE THE LATEST NEWS FROM US

Promotions

Q&A

Active ingredient profile

For partners

For suppliers

For agents

Logistics

Registration service

Patient support services

Our services

Commercial services

Distribution service

Contact us

Become a supplier

Become an agent

About us

About Felixpharma

Our profile

Our partners

2014 - 2022 by Synnex FPT Joint Stock Company